The Mumbai-based drug major on Monday reported a net profit of Rs 894 crore in the January-March period of 2020-21.
Shares of Sun Pharmaceutical Industries fell by over 4 per cent in morning trade on Tuesday a day after the company said its consolidated net loss stood at Rs 2,277 crore for the fourth quarter ended March 2022, mainly on account of a one-time exceptional loss.
The company's stock declined 4.12 per cent to Rs 851.50 on the BSE.
At the NSE, it tumbled 4.17 per cent to Rs 851.20 apiece.
The Mumbai-based drug major on Monday reported a net profit of Rs 894 crore in the January-March period of 2020-21.
Consolidated sales from operations stood at Rs 9,386 crore in the fourth quarter.
The company had reported sales from operations at Rs 8,464 crore in the year-ago period.
During the period under review, the company said it incurred a one-time cost of Rs 56.35 crore for restructuring operations in certain countries.
Total loss cited as an exceptional item during the fourth quarter, stood at Rs 3,936 crore.